Onconic Anticancer New Drug 'Nesuparib' Obtains Patent in Australia

[Financial News] Onconic Therapeutics announced on the 28th that the dual-target inhibitory anticancer new drug candidate Nesuparib has obtained a use patent ('PARP Inhibitor Resistant Cancer Treatment') in Australia. Until now, there have been clinical attempts to confirm the effect of combining PARP inhibitors with other classes of drugs such as ATR inhibitors in ovarian cancer patients with resistance (tolerance) to PARP inhibitors, but it was not confirmed that administering another PARP inhibitor alone to the same patient had a therapeutic effect.
However, Nesuparib has been recognized for its patent as it has been confirmed to have a therapeutic effect even when administered alone to solid tumors with resistance (tolerance) to existing PARP inhibitors.
In particular, Nesuparib is a next-generation synthetic lethality anticancer new drug candidate that dual-targets PARP and Tankyrase, meaningfully providing a new treatment opportunity for patients who failed anticancer treatment due to resistance (tolerance) after administering existing approved PARP inhibitors.
Nesuparib is a dual-target anticancer drug that simultaneously inhibits 'PARP (Poly ADP Ribose Polymerase)', which is involved in the repair of DNA damage in cancer cells, and Tankyrase (TNKS), which affects the growth and progression of cancer.
Based on the specificity of this mechanism, Nesuparib has acquired patent rights to treat solid tumors with resistance to existing PARP inhibitors, especially solid tumors with homologous recombination deficiency (HRD), through the administration of Nesuparib to patients who cannot be treated with PARP inhibitors. It is known that the resistance incidence rate of existing PARP inhibitors exceeds 50% within two years.
Currently, Nesuparib is undergoing clinical trials 1b/2 for pancreatic cancer and phase 2 for endometrial cancer. In particular, pancreatic cancer was designated as an orphan drug (ODD) by the U.S. Food and Drug Administration (FDA) and the Korean Ministry of Food and Drug Safety in 2021, and in March, it was designated as an orphan drug for gastric cancer and gastroesophageal junction cancer by the FDA.
Along with this, Nesuparib is conducting research and development to expand various indications such as pancreatic cancer and ovarian cancer through combination therapy with MSD's Keytruda and Celltrion's Begzelma.
A representative of Onconic Therapeutics stated, "We plan to utilize the value and exclusive rights of Nesuparib as a new treatment for PARP-resistant solid tumor patients who did not see effects with existing PARP inhibitors through this patent acquisition," adding, "Through additional clinical development, we will expand the treatment indications of Nesuparib and provide new treatment options to meet unmet medical needs in the global anticancer market."
Meanwhile, the family patent of this patent has been filed in 21 countries and has been registered in Eurasia and the Republic of South Africa as well as Australia. The duration is until May 18, 2042.

vrdw88@fnnews.com Kang Jung-mo Reporter